Comparison · NCT01347580-sae
Ticagrelor In-Hosp vs Ticagrelor Pre-Hosp: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ticagrelor In-Hosp vs Ticagrelor Pre-Hosp: serious adverse events. Trial comparisons, record NCT01347580-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01347580-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.151 | 0.129 | 0.175 | wilson | |
| Risk in group 2 | 0.154 | 0.132 | 0.179 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00366 | -0.0365 | 0.029 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.976 | 0.788 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.972 | 0.755 | 1.25 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ticagrelor In-Hosp than on Ticagrelor Pre-Hosp | 273 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ticagrelor In-Hosp | Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days. | 143 | 950 | EG000 |
| Group 2 | Ticagrelor Pre-Hosp | Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days. | 140 | 908 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- within 30 days of study
Source ClinicalTrials.gov
Trial
- Title
- A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
- NCT number
- NCT01347580
- Phases
- PHASE4
- Conditions
- Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
- Interventions
- Ticagrelor, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2015-02-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01347580?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01347580-sae